Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens, Athens, Gr...
Saved in:
Main Authors: | Kosmas CE (Author), Skavdis A (Author), Sourlas A (Author), Papakonstantinou EJ (Author), Peña Genao E (Author), Echavarria Uceta R (Author), Guzman E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
by: Kosmas CE, et al.
Published: (2022) -
New and emerging lipid-modifying drugs to lower LDL cholesterol
by: Constantine E Kosmas, et al.
Published: (2021) -
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
by: Kosmas CE, et al.
Published: (2020) -
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023) -
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)